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Abstract
Loss of the PTEN tumor suppressor is a common occurrence in human prostate cancer, particularly in advanced disease. In
keeping with its role as a pivotal upstream regulator of the phosphatidylinositol 3-kinase signaling pathway, experimentally-
induced deletion of Pten in the murine prostate invariably results in neoplasia. However, and unlike humans where prostate
tumorigenesis likely evolves over decades, disease progression in the constitutively Pten deficient mouse prostate is
relatively rapid, culminating in invasive cancer within several weeks post-puberty. Given that the prostate undergoes rapid
androgen-dependent growth at puberty, and that Pten excisions during this time might be especially tumorigenic, we
hypothesized that delaying prostate-specific Pten deletions until immediately after puberty might alter the pace of
tumorigenesis. To this end we generated mice with a tamoxifen-inducible Cre recombinase transgene enabling temporal
control over prostate-specific gene alterations. This line was then interbred with mice carrying floxed Pten alleles. Despite
evidence of increased Akt/mTOR/S6K axis activity at early time points in Pten-deficient epithelial cells, excisions induced in
the post-pubertal (6 wk-old) prostate yielded gradual acquisition of a range of lesions. These progressed from pre-
malignant changes (nuclear atypia, focal hyperplasia) and low grade prostatic intraepithelial neoplasia (PIN) at 16–20 wks
post-tamoxifen exposure, to overtly malignant lesions by ,1 yr of age, characterized by high-grade PIN and microinvasive
carcinoma. In contrast, when Pten excisions were triggered in the pre-pubertal (2 week-old) prostate, neoplasia evolved over
a more abbreviated time-frame, with a spectrum of premalignant lesions, as well as overt PIN and microinvasive carcinoma
by 10–12 wks post-tamoxifen exposure. These results indicate that the developmental stage at which Pten deletions are
induced dictates the pace of PIN development.
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Introduction
Genetic alterations in a variety of different oncogenes and
tumor suppressor genes have been associated with human prostate
tumorigenesis (reviewed in [1]; [2]). Of these, mutations involving
the PTEN (phosphatase and tensin homolog deleted on chromo-
some 10) tumor suppressor are amongst the most commonly
encountered, with loss of function mutations being reported in
,30% of primary cancers, and in more than 60% of metastases
(reviewed in [3]). Echoing these findings, deletion of Pten in the
developing murine prostate leads to early onset and rapidly
progressive neoplasia [4–8]. PTEN’s importance lies primarily in
its ability to regulate the levels of membrane PI(3,4,5)P3 (PIP3)
generated by the actions of phosphatidylinositol 39-kinase (PI3K)
(reviewed in [9]). PTEN dephosphorylates PIP3, yielding
PI(4,5)P2, thus PI3K activity (for example, in response to receptor
protein tyrosine kinase activation) in Pten-deficient cells results in
higher and more sustained levels of PIP3. PIP3-dependent
pathways, in turn, regulate various cellular processes, including,
rate of protein translation, susceptibility to apoptosis and anoikis,
entry into the cell cycle, differentiation, and motility (reviewed in
[9]). Key effectors lying downstream of PIP3 that promote
tumorigenesis include such molecules as PDK1, Akt/protein
kinase B (PKB), and the two mammalian target of rapamycin-
containing complexes, mTOR1 and mTOR2 [10,11]. The PI3K/
AKT/mTOR pathway in particular often plays a fundamental
role in supporting cancer cell metabolism, growth, and survival
[12].
The ability to manipulate the mouse genome has allowed the
evaluation of genetic alterations potentially involved in human
prostate tumorigenesis, as well as the identification and preclinical
validation of molecular targets for potential pharmacological
intervention [13]. In the case of PTEN, loss of the cognate gene in
the murine prostate has been shown to trigger rapid onset of
disease, with prostatic intraepithelial neoplasia (PIN) and invasive
adenocarcinomas ensuing within a few weeks of puberty [4,14–
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lifespan of mice, such a rapid evolution of disease is not reflective
of disease progression in humans, that likely takes place over
decades as a consequence of an accumulation of genetic changes
and where intraepithelial lesions tend only to be observed beyond
middle age. Indeed, most cases of prostate cancer are diagnosed in
men over the age of 65 [19]. Thus far there has been a paucity of
mouse models of prostate cancer able to clearly delineate the
various pathological grades seen in the human disease, from the
earliest premalignant changes to overt invasive carcinoma and
metastasis [20].
There has been a need for mouse models that better mimic the
slow progression to cancer typical of human prostate tumorigen-
esis. One of the steps towards attaining this goal has been the
development of inducible systems that allow genetic alterations to
be confined to the prostatic epithelium of the mature gland, the
target tissue involved in the acquisition of genetic alterations over
the span of a human lifetime. To this end, we generated a murine
line, ARR2PB-CreER(T2), expressing a 4-hydroxy-tamoxifen
(OHT)-inducible Cre recombinase, Cre-ER(T2), under the control
of the ARR2-rat probasin composite promoter [21]. This novel
system allows temporal control over the timing of gene deletions in
the prostatic epithelium.
Since the prostate epithelium undergoes rapid growth at
puberty, we hypothesized that this might account for the rapid
progression of disease in mice expressing constitutive Cre-triggered
deletions of Pten. Supporting this idea, we found that OHT-
induced Cre-mediated Pten excisions in the gland after puberty led
to the very gradual development of a range of premalignant
lesions. Over the course of a year these mice went on to develop
high-grade PIN lesions as well as invasive carcinoma. The delayed
latencies occurred despite evidence of prominent activation of the
pro-tumorigenic Akt/mTOR/S6K pathway at all stages of the
disease. In support of the hypothesis that the timing of Pten loss is
an important variable in mouse prostate tumorigenesis, Pten
excisions triggered in the pre-pubertal prostate accelerated the
progression to PIN and microinvasive carcinoma.
Results
Prostate histopathology in OHT-treated
ARR2PBCreER(T2)6Pten
fl/fl mice
As Pten gene deletions in the prostate have been shown to lead to
rapid onset of tumorigenesis, we investigated the effects of delaying
Pten excisions until after the gland had developed. Thus,
ARR2PBCreER(T2)6Pten
fl/fl or Pten
fl/fl control mice were injected
with OHT daily for 5 consecutive days starting at 6 wks of age and
then sacrificed at either 4–10,16–20, or 30–40 wks p.i. In the 4–
10 wks p.i. group, ARR2PBCreER(T2)6Pten
fl/fl mice treated with
OHT demonstrated nuclear atypia and increased prominence of
nucleoli in sporadic cells within the prostatic epithelium (arrows -
Figure 1A(i) and (iii)), as well as early hyperplastic lesions at 4-
wks post-OHT mice (rectangle- Figure 1A(ii)) with these being
more obvious at 10-wks post-OHT mice (Figure 1A(iii)). At 16–
20 wks p.i. the premalignant phenotype became much more
evident, such that experimental animals displayed increased
cellular size and nuclear atypia, as well as abnormal cellular
morphology of luminal epithelial cells (Figure 1A(iv)). Of the 13
experimental animals, 11 contained focal areas with hyperplastic
lesions ranging from mild to pronounced, and 6 out the mice
exhibited advanced PIN lesions (Figure 1B(ii–iv) and Table 1).
Control animals did not display these phenotypic changes
(Figure 1B(i)) except perhaps for two mice with mild focal
thickening of the luminal epithelium likely due to hyperplasia
(Table 1). There was no additional progression past PIN lesions in
4 experimental animals when these were aged to 30–40 wks p.i.,
however, the PIN lesions became more prominent, and showed a
wider area of distribution within the prostate (data not shown).
Furthermore, none of the non-OHT exposed ARR2PB-
CreER(T2)6Pten
fl/fl, control Pten
fl/fl, or the ARR2PBCreER(T2)
mice developed any evidence of premalignant lesions in their
prostates (data not shown).
Increased proliferation in the epithelium of OHT-treated
ARR2PBCreER(T2)6Pten
fl/fl mice
The Ki67 marker was used to show the level of proliferation in
the prostatic epithelium of OHT-treated ARR2PBCreER(T2)6P-
ten
fl/fl mice. At 4–10 wks post-OHT treatment, Cre-positive
animals demonstrated increased numbers of luminal epithelial
cells positive for Ki67 (Figure 2B). This effect was much more
pronounced at 16–20 wks post-OHT and as would be predicted,
was especially striking in the hyperplastic and PIN lesions
(Figure 2D). In contrast, control Pten
fl/fl prostates treated with
OHT contained few, if any, Ki67-positive cells (Figure 2A and
C). These findings demonstrated that loss of Pten was accompa-
nied by a progressive increase in epithelial cell proliferation as
shown by quantification of Ki67-positive cells at 4–10 wks and 16–
20 wks (Figure 2E).
PIN lesions of ARR2PBCreER(T2)6Pten
fl/fl OHT-exposed
mice demonstrate Pten deficiency
When compared to the levels of Pten in the luminal epithelium
of control Pten
fl/fl animals (Figure 3A(i)), Pten protein deficiency
was evident in PIN lesions of ARR2PBCreER(T2)6Pten
fl/fl mice at
16–20 wks OHT p.i. (Figure 3A(ii)). At 4–10 wks p.i., Pten
deficiency wasseeninasmall numberof cells(arrowsFigure 3B(i–
ii)), and loss of Pten immunoreactivity was particularly evident in
hyperplastic regions (arrows Figure 3B(iii)). These results were
consistent with Pten deficiency being present in a subset of cells that
together with increased proliferation and additional genetic events
gradually evolved into the PIN lesions observed in the older mice.
As only a few cells in a given tubule tended to show loss of Pten
immunoreactivity at 4–10 wks post-OHT exposure, it suggested
that Pten excisions at the epithelial stem cell level may have been
infrequent.
Evidence for PI3K pathway activation in PIN lesions of
ARR2PBCreER(T2)6Pten
fl/fl mice 16–20 wks post-OHT
treatment
To assess PI3K pathway activity components known to be
affected by the loss of Pten were examined by immunohistochem-
istry of paraffin sections from mice 16–20 wks post-OHT
exposure, these included: AKT, mTOR, 4E-BP1, eIF4E and S6.
Levels of phospho-AKT and phospho-mTOR were upregulated in
the PIN lesions of OHT-treated ARR2PBCreER(T2)6Pten
fl/fl mice
(Figure 3A(iv,vi)). The levels of phospho-4E-BP1, eIF4E, and
phospho-S6-ribosomal protein immunoreactivity were also upre-
gulated in the PIN lesions (Figure 3A(viii,x,xii)), indicating that
the AKT/mTOR/S6K axis was activated in the prostatic lesions.
This feature, obvious in PIN lesions as these contained large
numbers of Pten deficient cells (Figure 3A(ii)), was also observed
in hyperplastic regions of 16–20 wks post-OHT treated experi-
mental mice and even in isolated tubular cells in mice at 4–10 wks
post-OHT treatment (data not shown).
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PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e3940Figure 1. Transition from the earliest stages of transformation to occur progressively in ARR2PBCreER(T2)6Pten
fl/fl mice following
OHT exposure. (A) Nuclear enlargement with prominent and multiple nucleoli is seen in the luminal epithelial layer at different times post-OHT; in
single cells at 4 wks post-OHT (arrows (i)); becoming more widespread at 8–10 wks post-OHT (arrows (iii)) and in the majority of cells in PIN lesions at
16–20 wks post-OHT (iv). Low grade hyperplasia is seen in the luminal layer at 4 wks post-OHT (rectangle (ii)). At 10 wks post-OHT, hyperplasia
became more pronounced and nuclear enlargement with prominent nucleoli and hyperchromasia became more prevalent (arrows (iii)). Early stages
of PIN, such as nuclear overlapping and mild tufting are noticeable by 10 wks post-OHT (iii). At 16–20 wks post-OHT more advanced PIN stages were
evident (iv), with overt tubular dysplasia while basement membranes remained unbreached. PIN was prominent and most cells within these lesions
showed nuclear enlargement, prominent nucleoli, hyperchromasia, and abnormal morphology (iv). (B) High grade PIN lesions were present in mice at
16–20 wks post-OHT. (i) While Pten
fl/fl controls showed normal morphology after OHT treatment, PIN lesions are seen 16–20 wks post-OHT
administration in ARR2PBCreER(T2)6Pten
fl/fl mice, with different categories of high grade PIN being evident; including as tufting, micropapillary and
flat atypia (ii), and cribriform structures (iii) and (iv) were seen in both focal intra-tubular as well as the more widespread lesions in the experimental
animals. Scale bars: 50 mm.
doi:10.1371/journal.pone.0003940.g001
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phospho-S6 ribosomal protein upregulation in pre-
neoplastic epithelial cell lesions
Pten-deficient cell numbers were higher in the juxta-luminal
epithelial regions of ARR2PBCreER(T2)6Pten
fl/fl prostates post-
OHT treatment and these were associated with cellular and
nuclear atypia, as well as hyperplastic regions and PIN
(Figure 3A(ii); Figure 3B(i–iii)). By performing immunohisto-
chemistry for Pten and phospho-S6 ribosomal protein on
sequential sections, we found that cells and regions lacking Pten
also expressed high levels of phospho-S6, even at 4–10 wks p.i.
This phenomenon was even evident within single cells at the
earliest time points (arrows Figure 3B(i,ii,iv,v)), becoming more
dramatic within Pten-deficient cells contained within hyperplastic
regions (arrows Figure 3B(iii,vi)). These results demonstrated
that there was a direct correlation between Pten-deficiency and
increased S6 kinase activity, and that this feature was present early
on, well before the appearance of histologically evident cellular
and nuclear atypia, or hyperplasia.
Progression to carcinoma in ARR2PBCreER(T2)6Pten
fl/fl
mice 42–52 wks post-OHT
Progression from PIN to invasive carcinomas was seen in
experimental animals at 42–52 wks post-OHT administration. We
found that the area composed of PIN lesions increased greatly with
aging, with multiple glands developing PIN (Figure 4 (i and ii)).
There were proliferating cells within these lesions as shown by
immunostaining with the Ki67 antibody (Figure 4 (iii) arrows)
and high levels of phospho-S6 expression (Figure 4 (iv)),
indicating that pAKT/pmTOR/pS6 pathway had remained
active. Immunohistochemistry for cytokeratins 1, 5, 10 and 14
(clone 34B12 from Dako), that stains basal cells, showed that while
normal glands within the same animal maintained basal cell
cytokeratin staining (arrows Figure 4 (v)), the PIN lesions in the
animals aged for 42–52 wks aged animals had progressed to
carcinoma as suggested by the lack of cytokeratin staining for basal
cells (red arrows Figure 4 (vi)).
Accelerated progression to PIN and microinvasive
carcinoma when Pten is deleted in the prostates of 2 wk-
old ARR2PBCreER(T2)6Pten
fl/fl mice
A wide range of lesions was seen in the prostates of mice that
had been injected with OHT at 2 wks of age and then aged for 4–
6 wks and 10–12 wks (Figure 5 and Table 2). Nuclear atypia
and abnormal cellular morphology, as well as hyperplastic regions
(Figure 5(i)) and low grade PIN lesions (Figure 5 (ii)) were
already evident in animals aged for 4–6 wks p.i. Importantly, at
10–12 wks p.i. the phenotype became much more pronounced
such that all of the experimental animals displayed increased cell
size and nuclear atypia, abnormal cellular morphology of luminal
epithelial cells, hyperplastic lesions, and high grade PIN (Figure 5
(iii–iv)). Two of the 6 experimental animals in this age group had
even developed microinvasive carcinoma (arrows in Figure 5(iii)).
Stromal thickening, suggestive of an invasive phenotype, was
noticeable in animals at 10–12 weeks p.i. (blue arrows Figure 5
(vi)). At both 4–6 wks and 10–12 wks p.i., Cre-positive animals
were found to have increased numbers of luminal epithelial cells
positive for the proliferation marker Ki67 (Figure 5 (v) shows a
representative experimental animal at 4–6 wks p.i) and were also
positive for phospho-S6 (Figure 5 (vi) shows a representative
experimental animal at 4–6 wks p.i).
Increased apoptosis observed in prostatic epithelium
following Pten gene deletion
TUNEL assay was used to show the level of apoptotic cells in
the prostatic epithelium of ARR2PBCreER(T2)6Pten
fl/fl mice
previously treated with OHT either at 2 wks and then aged for
6 wks p.i. (Fig. 6 (B)), or treated with OHT at 6 wks and then
aged for 4–10 wks p.i (Fig. 6 (D)). In both groups, Cre-positive
animals revealed increased numbers of apoptotic luminal epithelial
cells as compared to controls (p-value,0.001) as shown by the
quantification of TUNEL-positive cells (Figure 6E). These results
showed that loss of Pten was accompanied by a significant increase
in epithelial cell death.
Discussion
Prostate-specific promoters such as the composite probasin
promoter used herein have previously been employed to generate
a wide variety of transgenic lines [17,22–24]; reviewed in [18].
These have enabled evaluation of the consequences of prostate-
specific expression of genes implicated in human prostate cancer.
Germline knockout models, where all cells in the animal harbor
the genetic alteration, have also been used to study prostate
tumorigenesis (reviewed in [18]). However, owing to the lack of
cell-type specific deletion in the latter, it has been difficult to
attribute the resulting phenotypes solely to a defect within the
prostatic epithelium. Thus, in the last few years, conditional gene
alterations have been used to investigate the ability of specific
mutations to promote the development of prostate neoplasia
[17,25] (reviewed in [18]).
Various models of prostate cancer have shown that mutations in
tumor suppressors, or activation of oncogenes during androgen-
induced gland development at puberty can lead to prostate cancer.
In such models, however, tumor progression often occurs at an
accelerated pace with progression to adenocarcinomas and
invasive carcinomas being evident within a few weeks after
puberty [4,14–17]. For example, the PBCre46Pten
flox/flox prostate
cancer model [17]; (reviewed in [18]) has been shown to mimic
Table 1. Morphologic alterations in the prostates of ARR2PBCreER(T2)6Pten
fl/fl mice injected at 6 wks of age, and subjected to
histopathological analysis 16–20 wks post-OHT exposure.
Mouse Genotype
Abnormal cellular
morphology
1
Atypical nuclear
morphology
2 and increased
number of nucleoli Focal Hyperplasia PIN lesions
Control Pten
fl/fl None of 9 None of 9 Very small in 2 of 9 None of 9
Experimental ARR2PBCreER(T2)6Pten
fl/fl 10 of 13 13 of 13 11 of 13 6 of 13
1Abnormal cellular morphology refers to nuclear enlargement, prominent nucleoli, hyperchromasia, and deviations in cell size and appearance.
2Atypical nuclear morphology refers to nuclei displaying nuclear and nucleolar enlargement and increased number of nucleoli.
doi:10.1371/journal.pone.0003940.t001
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hyperplasia to PIN, to adenocarcinoma and metastasis. As such,
this appears to be one of the few murine models that replicates the
spectrum of grades and stages observed in human prostate cancer
[18]. However, the age at which invasive tumors are observed in
this model would correspond to early adulthood in humans and do
not accurately reflect the more protracted developmental time-
course of prostate cancer in humans.
Figure 2. There is increased cell proliferation in the luminal epithelia of ARR2PBCreER(T2)6Pten
fl/fl mice exposed to OHT.
Immunohistochemical analyses revealed increased numbers of proliferating cells within the luminal epithelium of ARR2PBCreER(T2)6Pten
fl/fl mice
treated with OHT at 6 wks of age as indicated by Ki67 staining, as shown by the dark dots and arrows in (B) and (D). (A) and (C) control Pten
fl/fl at
10 wks and 20 wks post-OHT; (B) ARR2PBCreER(T2)6Pten
fl/fl at 10 wks post-OHT and a (D) a representative PIN lesion in a ARR2PBCreER(T2)6Pten
fl/fl
mouse at 20 wks post-OHT. Scale bar: 50 mm. (E) Quantification of the percentage of proliferating cells in control and ARR2PBCreER(T2)6Pten
fl/fl aged
for 4–10 wks and 16–20 wks post-OHT injections. There is a significant increase in the percentage of proliferating cells in the PIN regions of 16–20 p.i.
experimental animals both over control animals and the normal regions within the experimental animals (p-value,0.001).
doi:10.1371/journal.pone.0003940.g002
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over the timing of genetic alterations are attractive as they allow
phenotypic analyses of mutations in the context of the mature, or
even aged, prostate gland. The inducible transgenic mouse model
we previously developed [21] has allowed us to induce prostate
luminal epithelial cell-specific gene excisions in a temporally
controlled manner. This is a valuable feature given that genetic
and epigenetic alterations accumulated by the mature gland likely
play a role in driving progression of prostate cancer in humans.
Indeed, we found that Pten excisions in prostates of 6 wk-old
ARR2PBCreER(T2)6Pten
fl/fl resulted in a very gradual progression
to PIN and invasive carcinoma. Our findings are in agreement
with the recently published results of Ratnacaram et al., [26] who
showed that the CreER(T2) expressed under the control of the
PSA (prostate specific antigen) promoter yielded a similarly slowed
pace of disease progression when crossed onto the Pten
fl/fl
background. In our experiments, where we used 10–fold less
OHT (0.1 mg per day) than Ratnacaram et al., [26] (1 mg per
day), to activate CreER(T2) over a one-week period, we obtained
a very similar pattern of disease progression stemming from Pten
deletion in the adult animals. These two sets of results, using two
different prostate-specific promoter transgene systems to drive
CreER(T2) recombinase expression, support the idea that the
developmental stage at which Pten is excised can affect the pace of
prostate tumorigenesis.
We have shown that Pten deletions, in the mature prostate leads
to a wide range of pre-malignant lesions, and as illustrated by
Figure 1, even very early lesions could be resolved. We also
obtained immunohistochemical evidence of cell signaling aberra-
tions, consistent with the loss of Pten, and these were discernable
early on (Figure 3B) within isolated populations of epithelial cells.
For example, Pten loss was accompanied by increased pS6 levels
Figure 3. Downstream components of the PI3K signaling pathway are activated in PIN lesions of ARR2PBCreERT26Pten
fl/fl mice post-
OHT exposure. (A) Immunohistochemistry showing decreased Pten levels in a representative PIN lesion ((ii) bottom panel); top panel (i) shows Pten
levels in prostate epithelium of control Pten
fl/fl mice. Immunohistochemistry revealed increased levels of phospho-AKT, phospho-mTOR, phospho-4E-
BP1, eIF4E, and phospho-S6 (bottom panels (iv); (vi); (viii); (x); (xii) respectively) in PIN regions of positive animals (bottom panels) as comparedt o
controls (top panels (iii); (v); (vii); (ix); (xi)). (B) Pten loss in the prostatic epithelium is associated with increase in pS6 ribosomal protein levels in the
preneoplastic phase of ARR2PBCreER(T2)6Pten
fl/fl mice post-OHT. Serial sections stained with either anti-Pten or anti-pS6 antibodies showed that loss
of Pten could be correlated with increased phospho-S6 signal and that this could be detected at the single cell level during early time points post-
OHT (arrows), even at a time when cellular and nuclear atypia were not present; as indicated by the red arrows - (ii) and (vi) 4 wks; (iii) and (vii) 8 wks;
(iv) and (viii) 10 wks post-OHT. (i) and (v) show Pten, and phospho-S6 immunoreactivity, respectively, in serial sections form the prostate of a Pten
fl/fl
control mouse 8 wks post-OHT. Scale bars: A (i–xii), 100 mm; B (i–vi), 37.5 mm.
doi:10.1371/journal.pone.0003940.g003
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Thus, although loss of the Pten tumor suppressor and increased
PI3K pathway signaling is a key initiating factor in tumorigenesis,
it appears that additional cytogenetic or epigenetic events must
occur prior to the development of the PIN lesions as observed at
later stages in our mice (Figure 1B). Interestingly, we did not
observe progression past high grade PIN lesions until mice had
been aged for almost a year post-OHT administration (Figure 4).
The nature of the acquired genetic events required to promote
tumor progression in our model remain to be elucidated. The
application of new genomics and proteomics techniques to our
model, with its gradual stepwise development of pathological
lesions, could be useful in identifying sequences of alterations of
potential relevance to human prostate cancer, and in particular,
cancers featuring the loss of PTEN.
In contrast to the results obtained when Pten deletion was
triggered by OHT in mice at 6 wks of age, Pten excisions induced
immediately prior to the onset of puberty led to more rapid pace of
disease progression, with PIN lesions already being present at 4–
6 wks post-OHT (Figure 5), and high grade PIN lesions and
microinvasive carcinoma developing at 10–12 wks post-OHT
(Figure 5). This result was striking given that progression past PIN
Figure 4. Transition from PIN to invasive carcinoma is seen in ARR2PBCreER(T2)6Pten
fl/fl mice exposed to OHT and aged for 42–
52 wks. (i) Widespread high grade PIN lesions were seen in multiple glands within the prostates of experimental animals at 42–52 wks post-OHT, (ii)
with abnormal cellular and nuclear morphology and microinvasive lesions (arrows). (iii) Proliferating cells within these lesions were detected by
immunostaining with the anti-Ki67 antibody (arrows; arrowhead shows a mitotic figure) and high levels of phospho-S6 expression were also detected
(iv). Representative immunohistochemical analysis using an antibody against high molecular cytokeratins 1,5,10, and 14 that stains basal cells:
although basal cytokeratin staining was present within normal-appearing glands (v) (black arrows), with progression to invasive carcinoma there was
a lack of cytokeratin staining (vi) (red arrows) within the same prostate. Scale bars: (i), 100 mm; (ii–vi), 25 mm.
doi:10.1371/journal.pone.0003940.g004
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fl/fl mice exposed to OHT at 2 wks of age. ARR2PBCreER(T2)6Pten
fl/fl injected at
2 wks of age displayed a wide range of lesions by 10–12 wks post-OHT: (i) hyperplastic lesion, (ii) PIN, (iii) high grade PIN with occasional
microinvasive cells (arrows), (iv) high grade PIN lesions with a wide distribution area, stromal invasion of epithelial cells (yellow arrowheads) and
displaying stromal thickening (blue arrows), (v) increased proliferation in a positive mouse aged for 6 wks as indicated by Ki67 staining, (vi) positive
phospho-S6 staining of a positive animal at 6 wks post-OHT). Scale bars: (i–iii and v–vi), 50 mm; (iv), 100 mm.
doi:10.1371/journal.pone.0003940.g005
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triggered at 6 wks of age. For the purposes of comparison, we also
established the constitutive PBCre46Pten
flox/flox model that pro-
gresses rapidly from PIN to adenocarcinoma and metastases. In
our colony, disease progression in these mice was modestly delayed
(by a few weeks) as compared to what was reported by Wang et al,
[4](Table 3), the PBCre46Pten
flox/flox mice developed invasive
carcinomas and adenocarcinomas at a time when the ARR2PB-
CreER(T2)6Pten
fl/fl mice treated with OHT at 2 wks of age, were
starting to develop microinvasive carcinomas. Thus, in our model,
excisions of Pten induced at 2 wks of age more closely resembled
the phenotype observed in PBCre46Pten
flox/flox mice, while delaying
Pten excision until after puberty greatly slowed the pace of disease
development (Table 3). The importance of the timing of Pten
deletions was also highlighted by Backman et al. [5] using the
MMTVCre6Pten
fl/fl mouse model. In this case, early Pten deletions
led to epithelial hyperplasia as early as 5 days of age and high-
grade PIN and prostate carcinoma by 2 wks of age.
What accounted for the more aggressive disease course when
Pten excisions were induced prior to gland maturation? Growth
factors and other signals that are able to drive the PI3K pathway
may differ between the juvenile and adult glands. For example,
fibroblast growth factor 10 expression is prominent in the
mesenchyme surrounding the developing prostate but is then
switched off once the gland matures [27]. Furthermore, and
suggesting a mechanism whereby Pten deletion in the developing
gland might be especially tumorigenic, it was recently shown using
an in vivo epithelial-stromal reconstitution system that enhanced
mesenchymal expression of FGF10 led to the formation of
multifocal PIN lesions in mice [28]. Also, the loss of Pten just
prior to puberty, a time when epithelial proliferation is much more
prominent that in the mature gland, could mean that more cells
are placed at risk of transformation as a result of the chromosomal
instability that has been proposed to accompany loss of Pten
expression (reviewed in [29]).
While Pten excision obviously initiates the progression from
hyperplasia to PIN in our mice, lack of Pten by itself, especially in
the mature prostate, was not sufficient to generate the more
advanced lesions typical of the constitutively active Cre models of
Pten excision. While this might reflect excision frequencies within
the gland, it could also be due to an intrinsic difference between
the developing versus the mature gland that determines how the
cells respond to Pten loss. For example, it has been suggested that of
the lack of PTEN can be detrimental to tumour growth in the
absence of other mutations (reviewed in [29]), and complete loss of
this tumour suppressor can promote a senescence response that
opposes tumour progression [30]. It was found that while Trp53
inactivation in the mouse prostate failed to produce neoplasia, and
Pten inactivation produced non-lethal invasive prostate cancer after
a long latency, the combined inactivation of Trp53 and Pten in the
prostate elicited invasive prostate cancer in mice as young as two
weeks of age. In this case, Pten inactivation was found to trigger
growth arrest through a p53-dependent cellular senescence
response that was ‘rescued’ by the combined loss of Pten and
Trp53 [30]. It was also shown that Pten inactivation in the prostate
correlated with an increased proliferation rate of the epithelial
cells, but not with a reduced level of apoptosis [6]. This suggested
that while Pten inactivation promotes tumorigenesis there are also
mechanisms at play which may push the Pten-deficient cells
towards apoptosis. Although we found evidence of increased
apoptosis within our experimental animals treated either at 2 wks
or 6 wks of age (Figure 6), mice injected at 2 wks still progressed to
PINs and microinvasive cancer more rapidly suggesting that the
delayed latencies seen following Pten excision at 6 wks of age might
have been a consequence of tumorigenic changes being targeted to
a residual population of cells that had evaded the Pten loss-
induced senescence response. Lastly, it is possible that the prostate
progenitors responsible for the rapid pubertal growth of the gland
are less susceptible to the senescence-promoting effect of Pten
deficiency.
Using the PBCre46Pten
flox/flox model, Wang et al., [4] showed
that, Pten loss can lead to increased stem/progenitor cell
proliferation, which in turn may be associated with prostate
tumor initiation and progression. However, the authors did not
rule out the possibility that Pten loss might also be able to promote
the transformation of cells with limited replicative capacity,
providing them with self-renewal potential. In our model, Pten
deletion in the mature glad did not result in early invasive
adenocarcinomas and metastases, suggesting that loss of Pten
within a differentiating population with low proliferative potential
might only have a limited ability to augment residual proliferative
capacity. In the adult prostate the number of self-renewing cells
would be smaller than in the developing prostate, and this could be
a factor in the slower pace of tumor progression seen in our model.
Wang et al., [4] proposed that Pten loss may either increase the
pool of stem and early progenitor cells, or that it might be a
transforming event in non-actively dividing cells, leading them to
acquire self-renewing proliferative potential. Since we did not
observe rapid progression to invasive carcinoma and have not as
yet seen metastases, it is possible that in our model Pten deletions
are confined to cells with more limited self-renewal capacity. This
observation was reinforced by the results of inducing Pten excisions
in the developing prostate. While the progression through the
various disease stages is not as rapid as that seen in the
PBCre46Pten
flox/flox mice, we did see an accelerated phenotype as
compared to that observed when Pten was excised in the fully
developed prostate. In summary, our results suggest that the tumor
promoting effects of Pten deficiency are highly dependent on the
developmental stage of the prostate.
Table 2. Morphologic alterations in the prostates of ARR2PBCreER(T2)6Pten
fl/fl mice injected at 2 wks of age, and subjected to
histopathological analysis 10–12 wks post-OHT exposure.
Mouse Genotype
Abnormal cellular
morphology
1
Atypical nuclear
morphology
2 and increased
number of nucleoli Focal Hyperplasia PIN lesions
Microinvasive
carcinoma
Control Pten
fl/fl 0/4 0/4 0/4 0/4 0/4
Experimental ARR2PBCreER(T2)6Pten
fl/fl 6/6 6/6 6/6 6/6 2/6
1Abnormal cellular morphology refers to nuclear enlargement, prominent nucleoli, hyperchromasia, and deviations in cell size and appearance.
2Atypical nuclear morphology refers to nuclei displaying nuclear and nucleolar enlargement and increased number of nucleoli.
doi:10.1371/journal.pone.0003940.t002
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PLoS ONE | www.plosone.org 9 December 2008 | Volume 3 | Issue 12 | e3940Figure 6. There is increased cell death in the luminal epithelia of ARR2PBCreER(T2)6Pten
fl/fl mice exposed to OHT. There were increased
numbers of apoptotic cells within the luminal epithelium of ARR2PBCreER(T2)6Pten
fl/fl mice treated with OHT at 2 wks of age and aged for 6 wks (B)
and also in ARR2PBCreER(T2)6Pten
fl/fl mice treated with OHT and aged for 4–10 wks (D). (E) Quantification of the percentage of apoptotic cells in
control and ARR2PBCreER(T2)6Pten
fl/fl mice. There was a significant increase in the percentage of apoptotic cells over controls in
ARR2PBCreER(T2)6Pten
fl/fl injected with OHT either at 2 wks and 6 wks of age (p-value,0.001). Scale bar: 50 mm.
doi:10.1371/journal.pone.0003940.g006
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Genotyping
ARR2PB-CreER(T2) mice [21] were genotyped using the
following primers to verify for germline transmission: HPRT-FP:
cct tac ctt tca gaa gta ggc and CreER(T2)2: atc aac gtt ttc ttt tcg g.
Pten
flox/flox(fl/fl) mice were genotyped with Pten Flox-1: ctc ctc tac
tcc att ctt ccc and Pten Flox-2: act ccc acc aat gaa caa ac.
In vivo experiments
Animals (mixed 129;C57BL/6 background) were injected with
OHT at 6 wks of age, a time when stereological evaluation reveals
the prostate to be fully developed [31] and at 2 wks of age, a time
when prostate development is just commencing [31]. ARR2PB-
CreER(T2)6Pten
fl/fl mice and control mice lacking the Cre
transgene were injected i.p. with 0.1 mg OHT in corn oil vehicle
for five consecutive days and then allowed to age for the following
periods: 4–10, 16–20, 30–40, and 42–52 wks for the mice injected
at 6 wks of age; and for 4–6 and 10–12 wks post-injection (p.i.) for
mice injected with OHT at 2 wks of age. Furthermore, a cohort of
non-OHT-exposed ARR2PBCreER(T2)6Pten
fl/fl, Pten
fl/fl and
ARR2PBCreER(T2) mice were left to age for 16–20 wks to control
for the possibility of spontaneous Pten excisions. Mice were housed
in a viral antibody-free barrier facility in accordance with
Canadian Council on Animal Care, and the University of Calgary
Animal Care committee guidelines.
Histology and Immunohistochemistry
The dissected lower urogenital tracts of the mice were fixed in
10% formaldehyde, embedded in paraffin and sectioned at 5 mm.
Sections were de-paraffinized with xylene and graded alcohols and
every 10
th section was stained with hematoxylin and eosin (H&E)
for microscopy. For immunohistochemistry, sections were de-
paraffinized as above and antigen retrieval was performed using
10 mM sodium citrate, pH 6.0. Antibodies used were mouse anti-
Pten antibody (1:120); mouse anti-phospho-AKT (1:200); rabbit
anti-phospho-mTOR (1:7); rabbit anti-phospho-4E-BP1 (1:5);
rabbit anti-eIF4E antibody (1:10); rabbit anti-phospho-S6 ribo-
somal protein (Ser 240/244) antibody (1:100) (all from Cell
Signaling). Anti-high molecular weight cytokeratin antibody clone
34BE12 (1:100) was from Dako; and either the Vectastain Elite
mouse IgG kit or the rabbit IgG ABC kit from Vector
Laboratories were used as the secondary reagents. Color
development was performed with DAB substrate (Sigma-Aldrich)
and sections were counterstained with hematoxylin.
Apoptosis assay
The dissected lower urogenital tracts of the mice were fixed in
10% formaldehyde, embedded in paraffin, and sectioned at 5 mm.
Sections were de-paraffinized with xylene and graded alcohols
prior to the TUNEL assay, which was performed with the
ApopTag peroxidase in situ apoptosis detection kit according to the
manufacturer’s instruction (Chemicon International, Inc., Teme-
cula, CA).
Quantification of proliferation and apoptosis
The proliferation index was determined as the percentage of
Ki67-positive cells over total cells counted. At least 500 cells per
animal were counted over 5 different fields of view and 3–4 mice
were included per group. Quantification of apoptosis was
performed in a similar manner by determining the percentage of
TUNEL positive cells over total number of cells, except that 1000
cells were counted per animal (n=3–4 mice per group). Student
T-Test (two-tailed; unequal variance) was used for statistical
analyses.
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